MediWound Posts Promising EscharEx Data For Chronic Wounds
MediWound Ltd (NASDAQ: MDWD) has announced results from its U.S. Phase 2 clinical study of EscharEx for the debridement of venous leg ulcers (VLUs).
Benzinga ·
Benzinga
